Sanara MedTech (SMTI) Q4 2025 earnings review
Core Surgical Business Shines as Distractions Fade
Sanara MedTech enters 2026 as a leaner, 'pure-play' surgical business after shedding its cash-burning Tissue Health Plus (THP) unit. While reported Q4 revenue growth decelerated to 5% (13% adjusted for a prior-year Hurricane Helene bump), the underlying profitability profile has transformed. Gross margins stabilized at a stellar 93%, and Adjusted EBITDA for the quarter reached $4.7M. The company generated $6.8M in operating cash flow for the year, proving its core model works. Reaffirmed 2026 guidance targets 13-17% revenue growth, suggesting management expects the current adjusted growth rate to persist.
🐂 Bull Case
Gross margins sustained at 93% in Q4 (up from 91% a year ago). With the THP segment discontinued, the highly profitable core surgical business is now the sole driver of the P&L, yielding $17.0M in FY25 Adjusted EBITDA.
Sanara generated $3.9M of operating cash flow in Q4 alone, capping off $6.8M for the full year. This is a massive reversal from the cash-burn narrative of previous quarters and provides self-funding capacity for R&D.
🐻 Bear Case
Even adjusting for the Q4'24 Hurricane Helene anomaly, top-line growth decelerated to 13% YoY, down significantly from the 20%+ growth rates seen in Q1 through Q3 of 2025.
Operating expenses jumped 13% YoY in Q4, driven by a 130% spike in R&D ($2.0M) and a $1.8M noncash IP asset impairment. Transitioning to new products will require continued heavy investment.
⚖️ Verdict: 🟢
Bullish. The strategic decision to cut THP losses in Q3 is already paying dividends. Sanara is now a highly profitable, cash-flowing, high-margin surgical player. If they hit their 13-17% FY26 growth targets, the underlying operating leverage will drive significant bottom-line expansion.
Key Themes
Vizient Contract Expands Market Access
Sanara's BIASURGE product secured an Innovative Technology contract with Vizient, effective January 1, 2026. Vizient is the nation's largest provider-driven healthcare performance improvement company. This pre-negotiated pricing agreement provides frictionless access to Vizient's massive network of hospitals, acting as a major catalyst to re-accelerate top-line growth in FY26.
Decelerating Top-Line Growth
Decelerating. Adjusted YoY revenue growth has stepped down sequentially throughout 2025: 26% in Q1, 28% in Q2, 22% in Q3, and now 13% in Q4. While management reaffirmed 13-17% growth for FY26, the company is clearly moving past its hyper-growth 'early innings' phase into a more mature, steady expansion rate.
Transformation to Pure-Play Surgical Yields Operating Leverage
Stable. By classifying the failed Tissue Health Plus (THP) unit as discontinued operations (which carried a massive $37.2M net loss in FY25, largely due to impairments), Sanara's core financials now reflect reality. Gross margins are stable at 93%, driven by lower manufacturing costs for CellerateRX Surgical and favorable product mix. This leverage is what allowed full-year Adjusted EBITDA to nearly double to $17.0M.
R&D Spend and Asset Impairments Weigh on GAAP Earnings
Despite strong Adjusted EBITDA, Sanara reported a Q4 net loss from continuing operations of $1.1M. This was driven by a $1.8M non-cash write-down of IP assets (related to the strategic shift away from non-surgical products) and a 130% surge in R&D to $2.0M, primarily for soft tissue product enhancements. Investors must monitor if this elevated R&D run-rate is structural.
Other KPIs
Decelerating. Grew 5% YoY reported (or approximately 13% adjusted for Q4'24 anomalies). This segment remains the dominant engine of the company, representing 90% of total revenue. Growth was driven by deeper penetration of existing medical facilities and independent distributor network expansion.
Stable/Decelerating. Growth slowed to just 2% YoY, a stark contrast to the 18-25% growth rates seen earlier in 2025. This segment requires monitoring to see if it is losing market share or simply facing temporary ordering headwinds.
Reversing. A massive improvement from using $23.8 thousand in FY24. Q4 alone provided $3.9M. This positive cash generation significantly de-risks the balance sheet, allowing the company to service its $46.0M in long-term debt without requiring dilutive equity raises.
Guidance
Accelerating slightly vs the Q4 exit rate. The midpoint of $118.5M implies 15% YoY growth over FY25's $103.1M. This matches the adjusted growth rate from Q4 and assumes steady execution of the commercial strategy and new tailwinds from the Vizient contract.
Key Questions
Impact of Vizient Contract
The Vizient contract for BIASURGE went into effect on January 1, 2026. How quickly do you expect this to translate into measurable revenue acceleration, and does FY26 guidance fully capture this upside?
R&D Spend Run-Rate
R&D expense jumped 130% YoY in Q4 to over $2.0 million. Is this elevated level the new baseline as you prepare for the OsStic launch in 2027, or were there one-time developmental costs in the quarter?
Bone Fusion Slowdown
Bone fusion products grew only 2% YoY in Q4, a sharp deceleration from the double-digit growth seen earlier in the year. What dynamics are driving this, and what is the strategy to re-accelerate the portfolio?
Capital Allocation
With THP officially discontinued and the company generating nearly $4 million in operating cash flow this quarter, how does management plan to deploy the $16.6 million in cash on the balance sheet?